Single User License
INR 129300
Site License
INR 258600
Corporate User License
INR 387900

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Diabetic Peripheral Neuropathy-Pipeline Review, H2 2015

Diabetic Peripheral Neuropathy-Pipeline Review, H2 2015


  • Products Id :- GMDHC6908IDB
  • |
  • Pages: 59
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Diabetic Peripheral Neuropathy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diabetic Peripheral Neuropathy-Pipeline Review, H2 2015', provides an overview of the Diabetic Peripheral Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Peripheral Neuropathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Diabetic Peripheral Neuropathy Overview 7

Therapeutics Development 8

Pipeline Products for Diabetic Peripheral Neuropathy-Overview 8

Pipeline Products for Diabetic Peripheral Neuropathy-Comparative Analysis 9

Diabetic Peripheral Neuropathy-Therapeutics under Development by Companies 10

Diabetic Peripheral Neuropathy-Therapeutics under Investigation by Universities/Institutes 11

Diabetic Peripheral Neuropathy-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Diabetic Peripheral Neuropathy-Products under Development by Companies 15

Diabetic Peripheral Neuropathy-Products under Investigation by Universities/Institutes 16

Diabetic Peripheral Neuropathy-Companies Involved in Therapeutics Development 17

Acorda Therapeutics, Inc. 17

Astellas Pharma Inc. 18

Cebix Incorporated 19

Pfizer Inc. 20

ViroMed Co., Ltd. 21

Diabetic Peripheral Neuropathy-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

Antimunocel-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ASP-8477-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

BNV-222-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

capsaicin-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

CBX-129801-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drug for Pain-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ketoprofen-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

NRD-135SE1-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

PF-05089771-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

VM-202-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Diabetic Peripheral Neuropathy-Recent Pipeline Updates 48

Diabetic Peripheral Neuropathy-Dormant Projects 53

Diabetic Peripheral Neuropathy-Discontinued Products 54

Diabetic Peripheral Neuropathy-Product Development Milestones 55

Featured News & Press Releases 55

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 55

Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015 8

Number of Products under Development for Diabetic Peripheral Neuropathy-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Late Stage Development, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 13

Comparative Analysis by Early Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Products under Investigation by Universities/Institutes, H2 2015 16

Diabetic Peripheral Neuropathy-Pipeline by Acorda Therapeutics, Inc., H2 2015 17

Diabetic Peripheral Neuropathy-Pipeline by Astellas Pharma Inc., H2 2015 18

Diabetic Peripheral Neuropathy-Pipeline by Cebix Incorporated, H2 2015 19

Diabetic Peripheral Neuropathy-Pipeline by Pfizer Inc., H2 2015 20

Diabetic Peripheral Neuropathy-Pipeline by ViroMed Co., Ltd., H2 2015 21

Assessment by Monotherapy Products, H2 2015 22

Number of Products by Stage and Target, H2 2015 24

Number of Products by Stage and Mechanism of Action, H2 2015 26

Number of Products by Stage and Route of Administration, H2 2015 28

Number of Products by Stage and Molecule Type, H2 2015 30

Diabetic Peripheral Neuropathy Therapeutics-Recent Pipeline Updates, H2 2015 48

Diabetic Peripheral Neuropathy-Dormant Projects, H2 2015 53

Diabetic Peripheral Neuropathy-Discontinued Products, H2 2015 54

List of Figures

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015 8

Number of Products under Development for Diabetic Peripheral Neuropathy-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 14

Assessment by Monotherapy Products, H2 2015 22

Number of Products by Top 10 Targets, H2 2015 23

Number of Products by Stage and Top 10 Targets, H2 2015 23

Number of Products by Top 10 Mechanism of Actions, H2 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 25

Number of Products by Top 10 Routes of Administration, H2 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 27

Number of Products by Top 10 Molecule Types, H2 2015 29

Number of Products by Stage and Top 10 Molecule Types, H2 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Astellas Pharma Inc.

Cebix Incorporated

Pfizer Inc.

ViroMed Co., Ltd.

Diabetic Peripheral Neuropathy Therapeutic Products under Development, Key Players in Diabetic Peripheral Neuropathy Therapeutics, Diabetic Peripheral Neuropathy Pipeline Overview, Diabetic Peripheral Neuropathy Pipeline, Diabetic Peripheral Neuropathy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com